{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and posts on X and Bluesky that name this trial so far. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["ibrutinib","methotrexate","rituximab"],["ibrutinib","methotrexate","rituximab","procarbazine"]],"indication":"primary or secondary central nervous system lymphoma","name":"NCT02315326","nct_id":"NCT02315326","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct02315326. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"This is an open-label, non-randomized, single center, dose escalation, phase I/II study to establish the maximum-tolerated dose (MTD) of ibrutinib as a single agent in patients with refractory/recurrent PCNSL or refractory/recurrent SCNSL (Arm A).","label":"Arm A: Participants with refractory/recurrent PCNSL or refractory/recurrent SCNSL","type":"EXPERIMENTAL"},{"description":"The defined MTD from Arm A will then be used in an expansion cohort to further assess toxicity and clinical activity","label":"Arm B: Participants with refractory/recurrent PCNSL or refractory/recurrent SCNSL","type":"EXPERIMENTAL"},{"description":"Arm C will investigate the MTD of ibrutinib in combination with HD-MTX and to determine the safety and tolerability of the ibrutinib/HD-MTX combination regimen in PCNSL and SCNSL patients. To minimize drug-drug interaction between HD-MTX and Ibrutinib, Ibrutinib will not be administered concurrently with HD-MTX.","label":"Arm C: Participants with refractory/recurrent PCNSL or refractory/recurrent SCNSL","type":"EXPERIMENTAL"},{"description":"THIS IS ONLY ARM RECRUITING In Arm D, patients will be treated with 4 cycles of therapy. Methotrexate (3.5 g/m2) will be given at Dday 1 and Dday 15 of each cycle. Rituximab (500 mg/m2) will be given at Dday 0 and Dday 15 of each cycle. Vincristine (1.4mg/m2) will be given at Dday 1 and 15 of cycle 1 and 2 only. Procarbazine (100mg/m2) will be given of Day 1 of each cycle. Ibrutinib will be dosed at 560 mg daily. Arm D will have a safety lead-in of 6 patients. If more than 1 of 6 subjects develop a dose limiting toxicity (DLT) within the first 28 days of therapy (cycle 1), ibrutinib will be reduced to 420 mg daily dosing, and 6 additional patients will be enrolled. If more than 1 of 6 subjects develop a DLT, additional enrollment will be stopped.","label":"Arm D: Participants with refractory/recurrent PCNSL or refractory/recurrent SCNSL","type":"EXPERIMENTAL"}],"collaborators":["Pharmacyclics LLC.","Janssen Biotech, Inc."],"completion_date":{"date":"2026-01-28","type":"ACTUAL"},"conditions":["Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL)","Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)"],"enrollment":{"count":93,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Ibrutinib","otherNames":["Imbruvica™"],"type":"DRUG"},{"name":"HD- Methotrexate (MTX)","otherNames":[],"type":"DRUG"},{"name":"Rituximab + HD- Methotrexate (MTX)","otherNames":[],"type":"DRUG"},{"name":"procarbazine","otherNames":[],"type":"DRUG"}],"last_update":"2026-02-02","lead_sponsor":"Memorial Sloan Kettering Cancer Center","official_title":"A Phase I/II Trial of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2026-01-28","type":"ACTUAL"},"primary_outcomes":[{"measure":"define the Maximum Tolerated Dose (MTD) of ibrutinib (phase I)","timeFrame":"1 year"},{"measure":"progression free survival (phase II)","timeFrame":"2 years"},{"measure":"define the Maximum Tolerated Dose (MTD) of ibrutinib in combination with high-dose Methotrexate (HD-MTX)","timeFrame":"1 year"}],"references":[{"citation":"Krebs S, Mauguen A, Yildirim O, Hatzoglou V, Francis JH, Schaff LR, Mellinghoff IK, Schoder H, Grommes C. Prognostic value of [18F]FDG PET/CT in patients with CNS lymphoma receiving ibrutinib-based therapies. Eur J Nucl Med Mol Imaging. 2021 Nov;48(12):3940-3950. doi: 10.1007/s00259-021-05386-0. Epub 2021 May 8.","pmid":"33966087","type":"DERIVED"},{"citation":"Grommes C, Tang SS, Wolfe J, Kaley TJ, Daras M, Pentsova EI, Piotrowski AF, Stone J, Lin A, Nolan CP, Manne M, Codega P, Campos C, Viale A, Thomas AA, Berger MF, Hatzoglou V, Reiner AS, Panageas KS, DeAngelis LM, Mellinghoff IK. Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma. Blood. 2019 Jan 31;133(5):436-445. doi: 10.1182/blood-2018-09-875732. Epub 2018 Dec 19.","pmid":"30567753","type":"DERIVED"}],"start_date":{"date":"2014-12-08","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)","url":"https://clinicaltrials.gov/study/NCT02315326"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct02315326"}